In a study published yesterday in PLOS Medicine, researchers at the Johns Hopkins Bloomberg School of Public Health compared internal Pfizer documents to published studies on the drug Neurontin and found that "trial...
Category: pharma
In a study published yesterday in PLOS Medicine, researchers at the Johns Hopkins Bloomberg School of Public Health compared internal Pfizer documents to published studies on the drug Neurontin and found that "trial publication was not a transparent, or accurate...record for the numbers of participants randomized and analyzed for efficacy." In one case, "the description in the publication did not include data from 40% of participants actually randomized in the trial."
It's not the first time we've heard that drug-company sponsored studies might be suspect, but this study advances the story. And it was made possible only because of the unusual circumstance that the internal Pfizer documents became available through litigation.
The study was promoted in...
Two weeks ago, I posted...
Two weeks ago, I posted an item calling out Ezekiel Emanuel, the noted oncologist, biologist, and former White House adviser, for an Op-Ed he wrote in The New York Times. I said the story, about a pressing shortage of cancer drugs, was poorly done. And I arrogantly noted that almost any journeyman science writer, with far less credentials and public esteem than Emanuel, could do a better job. "Never send a man to do a journalist's job," I wrote.
Now, it's time to do a little ground-truthing on that. A number of science...
©2010 Knight Science Journalism at MIT. All Rights Reserved.